CHEPLAPHARM has held the rights for Atacand and Atacand Plus in 28 European markets since 2018.

In the fall of last year, CHEPLAPHARM agreed with AstraZeneca to also acquire the global rights (excluding the US) for these two products. The acquisition was finally successfully completed in the last week of December.

Atacand (Candesartan Cilexetil) is a prescription drug that is used to treat heart failure and high blood pressure. The product was developed in collaboration between AstraZeneca and Takeda and first launched in 1997.

AstraZeneca and CHEPLAPHARM have agreed that AstraZeneca will continue to manufacture and supply Atacand and Atacand Plus and to continue marketing the drugs in the respective territories for a three-year transition period. The transfer of the marketing authorizations and the integration of the product into the CHEPLAPHARM manufacturing and distribution network is therefore expected to be completed three years after the closing of the transaction. AstraZeneca received a payment of $ 250 million upon completion of the transaction and will receive additional payments of $ 100 million and $ 50 million in the first half of 2021.

'We have been planning to take over the global rights for Atacand since 2018 and are proud that it is now finally taking place,' said CHEPLAPHARM's CEO Sebastian F. Braun.

Contact:

Email: cheplapharm.com

(C) 2021 Electronic News Publishing, source ENP Newswire